|
|
| RICHARD,SANDRINE; SELLE,FRÉDÉRIC; LOTZ,JEAN-PIERRE; KHALIL,AHMED; GLIGOROV,JOSEPH; SOARES,DANIELE G.. |
| ABSTRACT It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways.... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Breast cancer; Dimerization; HER2/3; Monoclonal antibody; Pertuzumab; Trastuzumab. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652016000200565 |
| |
